Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.45 |
| ▸ | IL1R1 | P14778 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27696454 | 0.82 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL7169102 | 0.80 | KDM4E (0.45) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL6213376 | 0.80 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL13438866 | 0.80 | HRH3 (0.55) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| Iodide SCHEMBL6216315 | 0.79 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| Bromide SCHEMBL6215742 | 0.79 | ALDH1A1 (0.44) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL6217658 | 0.78 | ALDH1A1 (0.46) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL7169417 | 0.78 | KDM4E (0.46) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL7174133 | 0.77 | ALDH1A1 (0.48) | ALDH1A1KDM4EMEN1KMT2AHPGD | |
| SCHEMBL4274631 | 0.77 | KDM4E (0.51) | ALDH1A1KDM4EMEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7608626-B2 | Substituted indolizines and derivatives as CNS agents | WYETH (US) | 2009-10-27 | — | — | US | claimed |
| CN-101094852-A | Substituted indolizines and derivatives as CNS active agents | WYETH CORP (US) | 2007-12-26 | — | — | CN | claimed |
| EP-1807427-A2 | SUBSTITUTED INDOLIZINES AND DERIVATIVES AS CNS AGENTS | Wyeth (US) | 2007-07-18 | — | — | EP | claimed |
| WO-2006050007-A2 | SUBSTITUTED INDOLIZINES AND DERIVATIVES AS CNS AGENTS | WYETH (US) | 2006-05-11 | — | — | WO | claimed |
| US-20060094752-A1 | Substituted indolizines and derivatives as CNS agents | WYETH (US) | 2006-05-04 | — | — | US | claimed |
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | claimed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | claimed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | claimed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | claimed |
| US-7608626-B2 | Substituted indolizines and derivatives as CNS agents | WYETH (US) | 2009-10-27 | — | — | US | disclosed |
| CN-101094852-A | Substituted indolizines and derivatives as CNS active agents | WYETH CORP (US) | 2007-12-26 | — | — | CN | disclosed |
| EP-1807427-A2 | SUBSTITUTED INDOLIZINES AND DERIVATIVES AS CNS AGENTS | Wyeth (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006050007-A2 | SUBSTITUTED INDOLIZINES AND DERIVATIVES AS CNS AGENTS | WYETH (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094752-A1 | Substituted indolizines and derivatives as CNS agents | WYETH (US) | 2006-05-04 | — | — | US | disclosed |
| US-6572664-B2 | Oxidation dyeing of keratin fibers | L'OREAL S.A. (FR) | 2003-06-03 | — | — | US | disclosed |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | L'OREAL S.A. (FR) | 2002-11-21 | — | — | US | disclosed |
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | BRETON PHILIPPE (FR) | 2002-01-10 | — | — | US | disclosed |
| EP-1129691-A2 | Compositions for dyeing keratinous fibers containing indolizine derivatives and dyeing method using same | L'OREAL (FR) | 2001-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002749-A1 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | ALDH1A1 897/4885KDM4E 1225/4885MEN1 3434/4885 |
| US-20020170121-A9 | Indolizine derivatives, compositions comprising at least one coupler chosen from indolizine derivatives and at least one oxidation base, and methods for using same | KRT18, INMT, IDO1 | ALDH1A1 897/4885KDM4E 1225/4885MEN1 3434/4885 |
| US-20060094752-A1 | Substituted indolizines and derivatives as CNS agents | HTR2C, HTR3A, HTR1A | ALDH1A1 1692/4885KDM4E 3785/4885MEN1 2850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.